Compare NOMD & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | PGEN |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | NOMD | PGEN |
|---|---|---|
| Price | $12.01 | $3.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $19.75 | $7.67 |
| AVG Volume (30 Days) | 1.9M | ★ 4.3M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.63% | N/A |
| EPS Growth | ★ 4.79 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $3,581,837,382.00 | $6,309,000.00 |
| Revenue This Year | $0.43 | $342.78 |
| Revenue Next Year | $2.12 | $478.46 |
| P/E Ratio | $8.07 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $11.04 | $0.65 |
| 52 Week High | $20.81 | $5.23 |
| Indicator | NOMD | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 45.73 |
| Support Level | $12.06 | $3.44 |
| Resistance Level | $12.45 | $3.92 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 30.95 | 16.35 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.